Abstract
Obesity is considered an epidemic that aggregates multiple metabolic complications that cause reduction in the quality of life and its expectancy. Among these complications, there is a non-alcoholic liver disease, which mainly involves steatosis and cirrhosis resulting from the inflammatory process. The development of an efficient therapy of easy availability, low cost and good acceptance…